Pharmaceuticals

Corcept Therapeutics' stock plummeted and it now faces legal probes after the FDA rejected its key drug, revealing the company was warned not to apply.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.

After a regulatory setback, Ultragenyx has resubmitted its BLA for UX111, a potential first-ever treatment for the devastating Sanfilippo syndrome type A.

An Austin-based tech company's platform, which integrates into doctors' workflows, has cut prescription costs for nearly 60,000 Ohio residents.

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

With stronger Phase 2 data for its ATH434 drug and a healthy cash reserve, Alterity Therapeutics is preparing for a pivotal trial and seeking partners.

A new dual-action tablet shows major promise for prostate cancer patients with BRCA mutations, poised to change the standard of care in Europe.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

Industry leaders at the GenScript Global Forum agree: the era of AI experimentation is over. Now, the hard work of scaling and building trust begins.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

NewcelX sharpens its focus on a Type 1 Diabetes cell therapy, but faces a competitive landscape and significant financial hurdles in its ambitious quest.

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

ENA Respiratory's INNA-051 nasal spray, a virus-agnostic shield, has begun Phase II trials, offering new hope for high-risk communities.

The Spanish pharma giant secures approval for the first oral antibiotic specifically for acne in China, targeting a multi-billion dollar dermatology market.